Stefan Dübel

Title: Innovations of Stefan Dübel: Pioneering Antigen-Binding Proteins

Introduction

Stefan Dübel, a distinguished inventor based in Braunschweig, Germany, has made significant contributions to the field of biomedical engineering through his innovative research and patent applications. With a portfolio of three patents, Dübel's work focuses primarily on antigen-binding proteins and their potential applications in cancer treatment.

Latest Patents

Dübel's latest patents showcase his expertise in developing novel therapeutic agents. The first patent details an antigen-binding protein against HER3, which specifically targets a conformational epitope formed by domains III & IV of the human epidermal growth factor receptor 3 (HER3). This invention encompasses various elements, including nucleic acid molecules encoding these proteins, vectors, and pharmaceuticals designed for use as medicaments. It further outlines a method for inhibiting tumor growth by administering therapeutically effective amounts of these innovative proteins.

The second patent addresses a composition and method for modifying the binding of antigen-binding polypeptides to specific antigens. This composition integrates a polypeptide with calmodulin and two immunoglobulin superfamily domains, alongside a calmodulin binding molecule and ions that influence the binding affinity of the polypeptide to the target antigen. This innovative approach may significantly enhance the efficacy of antigen binding in therapeutic settings.

Career Highlights

Stefan Dübel has established himself as a notable figure in the realm of research and development. He has worked at Mab Factory GmbH and the University of Stuttgart, where he harnessed his expertise to advance his research on antigen-binding proteins. His efforts have paved the way for potential breakthroughs in the treatment of cancer and other diseases.

Collaborations

Throughout his career, Dübel has collaborated with esteemed professionals, including Holger Thie and Michael Hust. These partnerships have facilitated a dynamic exchange of ideas and expertise, contributing to the successful development of his innovative patents.

Conclusion

Stefan Dübel's work exemplifies the power of innovation in addressing critical health challenges. His advancements in antigen-binding proteins not only highlight his inventiveness but also reflect his commitment to improving therapeutic options for cancer treatment. As he continues to explore the boundaries of biomedical research, Dübel remains an inspiring figure for aspiring inventors and researchers alike.